GEMALTO
14.5.2018 07:02:08 CEST | Business Wire | Press release
Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, is strengthening trust in the smart energy sector with an end-to-end security solution which protects the entire ecosystem. Deployed by smart meter makers and distribution systems operators, the offer provides seamless connectivity solutions, secure digital identities and security lifecycle management for the long life of smart meters, as threats and stakeholders evolve over time. The solution protects connected energy assets and the data they exchange, allowing people and businesses to trust the expanding smart grid.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180513005007/en/
Secure smart grids improve sustainability, efficiency and reduce
threats
Today’s highly successful smart grids have become
comprehensive IoT networks with millions of connected meters that share
massive real time data about people, businesses and energy consumption.
The valuable insight they provide enables consumers to save on energy
bills and utilities and energy players to better balance supply and
demand. It is also crucial information to help integrate renewable
energy sources, helping to improve sustainability. As the marketplace
and number of connections continues to expand by an estimated 30% each
year1
, so does the cyberattack surface. The motivations for
hacking this critical infrastructure are high and diverse: energy
consumption fraud, insight into households’ activity and absence, grid
instability, pressure on governments, ID theft. Digital security is
paramount to an efficient grid´s success.
Click to watch the IoT Smart Energy video
Gemalto protects and secures the expanding smart grid sector
The
dedicated Gemalto cybersecurity
solution for electric utilities
establishes a foundation of trust at
the very core of the ecosystem by establishing end-to-end security
between energy meters, data concentrators and energy companies’ back-end
systems. Rugged and reliable IoT connectivity
modules
ensure 24/7 data availability. A strong and unique
digital identity system is implemented at the manufacturing stage to
ensure devices and applications can strongly authenticate themselves,
proving their legitimacy to access sensitive data. Leading-edge encryption
technology
safeguards against data tampering and strong security
lifecycle management enables remote security and data access updates,
without costly truck rolls.
“The smart energy ecosystem is one of the most advanced in terms of security requirements because of the potentially disastrous consequences of malicious hacking,” said Guillaume Lafaix, senior vice president Mobile Services and IoT, Gemalto. “The Gemalto cybersecurity solution for Utilities ensures the integrity and confidentiality of smart meter data while defending against hacking and emerging threats that are typical to this business.”
To learn more about the Gemalto cyber-security solution for Utilities,
please visit us at African Utility Week from May 15-17 in Cape Town. Or
check our dedicated webpages:
Gemalto
at African Utility Week
Gemalto
smart metering solutions
Gemalto
security lifecycle management for Utilities
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com , or follow @gemalto on Twitter.
1 https://www.technocracy.news/index.php/2017/08/03/global-smart-grid-market-growing-at-30-per-year/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180513005007/en/
Contact:
Gemalto media:
Tauri Cox, +1 512 257 3916
North America
tauri.cox@gemalto.com
or
Sophie
Dombres, +33 4 42 36 57 38
Europe Middle East & Africa
sophie.dombres@gemalto.com
or
Jaslin
Huang, +65 6317 3005
Asia Pacific
jaslin.huang@gemalto.com
or
Enriqueta
Sedano, +52 5521221422
Latin America
enriqueta.sedano@gemalto.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom